ARCHIVES

Pfizer’s Withdrawal Of Mylotarg Signals Stronger FDA Resolve To Monitor Confirmatory Studies

This article is from The Cancer Letter archive.

Vol. 36 No. 24 | June 25, 2010

Download PDF Visit The Full Archive

Related Articles

Leyland-Jones Named Director of Emory’s Winship Cancer Institute

November 17, 2006

After the Plenary: Don Berry: In NeoALTTO & ALTTO Trials, Neoadjuvant Response Predicts Adjuvant

July 11, 2014

Want To Know What Cancer Research Projects Are Going On? CRESPAC Can Describe More Than 5,000

January 2, 1976

NSABP Breast Cancer Prevention Trial Reports Final Results On Tamoxifen

November 25, 2005

NCAB Removes Its Restrictions On PDQ Access, Permits NCI Staff To Decide

February 7, 1986

ASCO Releases Guideline On Larynx Preservation

July 28, 2006